Man Group PLC Cyma Bay Therapeutics, Inc. Transaction History

Man Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $30,834 - $50,289	-5,244 Reduced 22.34%	18,225 $158,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $75,570 - $147,150	23,469 New	23,469 $147,000
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $293,646 - $527,126	-44,900 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $488,512 - $651,948	44,900 New	44,900 $497,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.